1 / 27

ANTICANCER AND ANTI-HIV DRUGS DERIVED FROM AFRICAN AND OTHER PLANTS Gordon Cragg, Ph.D. NIH Special Volu

ANTICANCER AND ANTI-HIV DRUGS DERIVED FROM AFRICAN AND OTHER PLANTS Gordon Cragg, Ph.D. NIH Special Volunteer Natural Products Branch Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis

ostinmannual
Download Presentation

ANTICANCER AND ANTI-HIV DRUGS DERIVED FROM AFRICAN AND OTHER PLANTS Gordon Cragg, Ph.D. NIH Special Volu

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANTICANCER AND ANTI-HIV DRUGS DERIVED FROM AFRICAN AND OTHER PLANTS Gordon Cragg, Ph.D. NIH Special Volunteer Natural Products Branch Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis NCI-Frederick Fairview Center, Suite 206 P. O. Box B Frederick, MD 21702-1201, U. S. A. Phone: 301-846-5387; fax: 301-846-6178 e-mail: craggg@mail.nih.gov website: http://dtp.nci.nih.gov; http://dtp.nci.nih.gov/branches/npb/index.html

  2. Traditional Medicine and Drug Discovery* • 80% of the world population resides in developing countries • 80% of people in developing countries utilize plants to meet their primary health care needs • Global pop. ca. 6.3 billion  • ca. 4 billion people utilize plants to meet their primary health care needs *Farnsworth NR, et al. Medicinal Plants in Therapy. Bull. W.H.O. 63:965-981 (1985)

  3. PLANT-DERIVED DRUGS • Analgesics: Aspirin: Salix species/Europe • Morphine, Codeine;Papaver somniferum/ • Mesopotamia (Iran, Iraq) • Cardiotonic: Digitalin: Digitalis purpurea/UK-Europe • Malaria: Quinine: Cinchona spp./Amazonia • Artemsinin: Artemisia annua/China • Antihypertensive: Reserpine: Rauwolfia serpentina/India • Memory enhancement: Physostigmine: Physostigma • venenosum/West Africa • Muscle relaxant: Tubocurarine:Chondrodendron spp./ • Amazonia

  4. NATURE – THE SUPREME MOLECULAR ARCHITECT! Epothilone A docked in tubulin active site Epothilone A Isolated from gliding bacteria (Myxobacteria) Nettles et al., "The Binding Mode of Epothilone A on a,ß-Tubulin by Electron Crystallography" Science, 6 August 2004, Vol. 305, pp. 866-869 (Copyright AAAS)

  5. PLANT-DERIVED ANTICANCER DRUGS IN CLINICAL USE OR DEVELOPMENT • Vinblastine/Vincristine: Catharanthus roseus/Jamaica, • Philippines (originally from Madagascar) • Etoposide: Podophyllum species/ Eastern US, Himalayas • Paclitaxel/Docetaxel: Taxus species/NW US, Europe • Topotecan/Irinotecan: Camptotheca acuminata/China • Homoharringtonine: Cephalotaxus harringtonia/China • Flavopiridol: Synthetic based on rohutikine from • Dysoxylum binectariferum/India • Combretastatins: Combretum caffrum/S. Africa

  6. INTERNATIONAL COLLABORATION • Prior informed consent/permits from Source Country • Government and stakeholders. • Collaboration with Source Country Organizations. • Training and technology transfer. • Protection of environment and sustainable development. • Plans for benefit-sharing Dr. D. Soejarto U. Illinois at Chicago

  7. MICHELLAMINE BPotential Anti-AIDS Agent Discovery and Development • 1987: Collected liana Ancistrocladus korupensis leaves. • Korup National Park, Mundemba, S. West Cameroon. • Dr. Duncan Thomas (MBG) and Mr. Ndembe (Forestry Dept.). • New species (Thomas & Gereau, Novon, 1993, 3, 494-498). • 1989: Michellamine B isolated. Active against a range of HIV-1 • and HIV-2 strains (Boyd et al., J. Med. Chem, 1994, 37, 1740-45). • Sufficient isolated from fallen leaves for preclinical development.

  8. MICHELLAMINE B COLLABORATION: CAMEROON

  9. FEASIBILITY STUDYCULTIVATION OF A. KORUPENSIS

  10. A. KORUPENSIS CULTIVATION STUDIES • 1993: Contract for cultivation feasibility study awarded. • All studies performed in Korup region involving local population. • Extensive botanical and analytical survey: • - Distribution: One liana per hectare. - Dried leaf analysis (N=>1,000): Up to 4% (w/w) MB. • Nursery established at Mundemba. Cuttings of high-yielding • plants propagated. • MB content of 1,5 year old seedlings: 0.07-0.73%

  11. DEVELOPMENT OF MICHELLAMINE B • Formulation as diacetate salt. • Toxicology: Rodents, dogs, primates. • Toxic dose level close to anticipated effective • antiviral dose (narrow therapeutic index). • Development suspended. • Possibility of lead development (Bringmann, Wurzburg). • Novel antimalarial agents, the korupensamines, add • further promise for A. korupensis.

  12. POTENTIAL ANTI-HIV DRUG FROM HOMALANTHUS • NUTANS : PROSTRATIN • Dr. Paul Cox entered into a Covenant with healers of • Western Samoan village of Falealupo • Covenant signed with village chiefs and orators with • concurrence of Prime Minister and Parliament. • Use of Homalanthus nutans by healersrecorded • by Dr. Cox: Treatment of “yellow” fever. • $480,000 provided for schools, clinics, water supplies, • trails, aerial walkways, etc. • Endowment established for preservation of forest. • P.A.Cox, Pharmaceutical Biology, 2001, 39 (Supplement ), 33-40

  13. Samoan Traditional Healers in Village of Falealupo

  14. Potent activator of HIV expression in latently- infected T-cells • Licensed by NIH to the AIDS ReSearch Alliance of America • Agreement with Government of Samoa • Milestone payments on completion of Phase I, II and III clinical trials • Royalties totaling 20% of net revenues • Distribution between government, village community and healers’ • families

  15. Calophyllum teysmannii var. inophylloide. Sustainable source of potential anti-AIDS drug, calanolide B. Discovery from tree in Sarawak, Malaysia, promoted conservation and replanting of seedlings in clearcut regions, and led to establishment of the Sarawak Biodiversity Center for in-country research on drug discovery from local biodiversity D.D. Soejarto, University of Illinois at Chicago

  16. CALANOLIDES DEVELOPMENT • 1995: Calanolides licensed to Medichem Research Inc. • Synthesis of (+)-calanolide A supported by NCI SBIR grant • Negotiation with Sarawak State Govt. required by LOC 1996: Joint venture company, Sarawak Medichem Pharmaceuticals formed • Phase I trials of Calanolide-A completed/well tolerated • Phase II trials in progress • Calanolide B in preclinical development

  17. PARALLEL DEVELOPMENT OF HERBAL MEDICINES AND THE DISCOVERY OF NOVEL CONVENTIONAL DRUGS • Bioassay-guided isolation and chemical characterization • of active principle(s) • Provide markers for standardization of herbal products • Provide lead compounds for conventional drug • development

  18. Basic Philosophy Any herbal drug or botanical supplement to be considered for clinical trials must be botanically authenticated as well as chemically and biologically standardized. Dr. Norman Farnsworth, Director, UIC/NIH Center for Botanical Dietary Supplements Research

  19. Steps Required Prior to Clinical Assessment of Herbal Drugs/Botanical Dietary Supplements • Acquire plant material • Verify identity; taxonomic/microscopic/PCR • Check for pesticides; herbicides; heavy metals • Establish/select appropriate bioassay • Bioassay several types of extracts • In vitro • In vivo (if possible/relevant)

  20. Steps Required (continued) • Bioassay-guided isolation and chemical characterization of active principle(s) • Prepare the biologically and chemically standardized dosage form • Conduct stability studies • In vitro studies on standardized product • Metabolism (including interactions with p450s) • Pharmacokinetics • Toxicity • Mechanism of Action

  21. http://www.asnapp.org/ Thank you for visiting this website, which is intended to be a network hub for all stakeholders in Africa’s natural plant products sector. Through knowledge-sharing and information-exchange via this site, ASNAPP (Agribusiness in Sustainable Natural African Plant Products) seeks to create a knowledge community that will strengthen the continent’s capacity to develop this sector. In the interests of developing successful natural product agribusinesses, and thus helping to reduce poverty in rural communities, ASNAPP promotes collaboration and knowledge sharing with research and academic institutions, government, private enterprises, non-profit organizations, the donor community and civil Society. For this purpose, the ASNAPP website encourages information exchange in any of the following areas: Applied research and technology transfer Quality assurance and control Market linkages and development Enterprise and farmer association development Natural resource management Policy dialogue and advocacy

  22. These areas are the main thrust of ASNAPP’s activities for 2005, based on the following three new programmes funded by the United States Agency for International Development (USAID): The Partnership for Food Industry Development Program (PFID), managed by Rutgers University’s New Use Agriculture and Natural Plants Products Program. The Rural Livelihoods Activity in Southern Africa programme, run by the Michigan State University Partnership for Food Industry Develop Program – Fruits and Vegetables (MSU PFID – F & V) in conjunction with a consortium of partners. The Partnership for Sustainable Germplasm Development for Non-traditional Crops, a collaborative project involving various academic and research institutions as well as private enterprises in South Africa and Zambia. ASNAPP USARutgers University - Cook CollegeDepartment of Plant Biology and Plant Pathology59 Dudley Road, 381 Foran HallNew Brunswick, New Jersey 08901Professor Jim SimonCo-Principal Investigator and Quality Control Coordinator ASNAPP ProgramNew Use Agriculture and Natural Plants ProgramTel: +732 932-9711 Ext. 355/379Fax: +732 932-9377Email: jesimon@aesop.rutgers.eduWebsite: www.nuanpp.org Partner countries: Ghana, Rwanda, Senegal, South Africa, Zambia, USA

  23. Clinical Trials and Complementary and Alternative Medicine (CAM) While many CAM treatments have already been in use for a long time (sometimes for centuries), there is not the kind of scientific knowledge available about them that has been gained from studies of conventional medicine. Many people are already using CAM, and without this scientific knowledge, they may be at risk— for example, for serious effects from taking the wrong dose, using the treatment in the wrong way, or using it with another treatment with which it interacts.

  24. INTERNATIONAL AND REGIONAL COLLABORATION • AFASSA: Africa, Asia and South America • Co-ordinates activities of networks involved in natural product • research in Africa, Asia and South America. • Founded at Intercontinental Symposium on Natural Products • Research in Montevideo in December, 1999. NAPRECA SYMPOSIUM ADDIS ABABA 2003 Next symposium: Antananarivo, Madagascar August 9-12, 2005 Takelaka.dts.mg/rafita

  25. THANK YOU http://dtp.nci.nih.gov

More Related